- How to relate fibrin and microbial invasion, Robert Ariens, United Kingdom
- How to manage perioperative bleeding complications, Michael Desborough, United Kingdom
- How to treat immune thrombocytopenia, Waleed Ghanima, Norway
Programme Day 2
08.30 - 08.55
Meet the Expert
Hall 5
- Arterial thrombosis and coagulation defects, Zsuzsanna Bereczky, Hungary
- Drug induced platelet dysfunction, Alexander Bye, United Kingdom
- What is new in Von Willebrand disease, Jeroen Eikenboom, The Netherlands
- Thrombotic complications during pregnancy, Catherine Bagot, United Kingdom
08.55 - 09.20
How to . . .
Hall 5
- How to run a coagulation lab, Steve Kitchen, United Kingdom
- How to study NETS, Kimberly Martinod, Belgium
- How to understand the fibrin network, Nicola Mutch, United Kingdom
- How to diagnose and manage coagulopathies in hemoglobinopathies, Rafal Pawlinski, United States
- How to dissect the pathophysiology of TTP, Karen Vanhoorelbeke, Belgium
Meet the Expert
Hall 5
- Platelets and inflammation, Benoit Ho-Tin-Noé, France
- Biochemistry of Vitamin K, Leon Schurgers, The Netherlands
- Sex and thrombosis, Astrid van Hylckama Vlieg, The Netherlands
- Point of care tests in thrombosis and haemostasis, Dianne Kitchen, United Kingdom
- Paradox thromboembolism – patent foramen ovale, Francis Couturaud, France
09.20 - 09.30
Short Break
09.30 - 10.30
Focus Symposium
Thrombosis and Cancer
Hall: Lomond
Moderator: Hanne Skille (Norway)
- 9.30 – 10.00: VTE therapy in patients with Cancer, Manuel Monreal, Spain
- 10.00 – 10.15: Platelets promote metastatic dissemination in mouse and human models in vivo and are associated with reduced survival in lung adenocarcinoma patients, Stephanie Hyslop, Australia
- 10.15 – 10.30: The impact of second cancer on the risk of cancer associated venous thromboembolism; a Danish nationwide study, Inger Lise Gade, Denmark
Focus Symposium
Treatment of Haemophilia
Hall: Alsh
Moderator: Johannes Thaler (Austria)
- 9.30 – 10.00: Non-substitutive treatments in Haemophilia, Michael Makris, United Kingdom
- 10.00 – 10.15: A fully-human bispecific antibody for the treatment of hemophilia A, John Blackwood, United Kingdom
- 10.15 – 10.30: Emicizumab demonstrates long term efficacy and tolerability in a broad population of persons with haemophilia A (PwHA) with or without FVIII inhibitors: pooled data from four HAVEN studies, Michael Callaghan, United States
Focus Symposium
Translational Science
Hall: Boisdale
- 9.30 – 10.00: Microparticles, ready for the clinics?, Françoise Dignat-George, France
- 10.00 – 10.15: In Silico Peptide Design: from molecular mechanism to novel therapeutic treatments for inflammatory diseases, Kanin Wichapong, The Netherlands
- 10.15 – 10.30: Targeting CXCL1-deposition on the vessel wall with a tick-derived protein, Ingrid Dijkgraaf, The Netherlands
Focus Symposium
Anticoagulant Proteins
Hall: Carron
Moderators: Tassos Petri (United Kingdom) and Thomas Kümler (Denmark)
- 9.30 – 10.00: Protein S – at the centre of haemostatic regulation, Josefin Ahnström, United Kingdom
- 10.00 – 10.15: Characterisation of citrullinated TFPI and truncated TFPI constructs by PAD4 in model and plasma systems, Stella Thomassen, The Netherlands
- 10.15 – 10.30: Molecular, biological and clinical characterization of variants affecting the C-terminal end of antithrombin, Bravo-Perez Carlos, Spain
10.30 - 11.00
Coffee Break & Poster Viewing
11.00 - 11.30
State of the Art
A dual role for platelets in fibrinolysis
United Kingdom
Hall: Lomond
Moderator: Sabine Eichinger (Austria)
State of the Art
Vascular calcification
The Netherlands
Hall: Alsh
Moderators: Pierre Morange (France) and Banne Neneth (The Netherlands)
11.30 - 12.00
State of the Art
Management in Von Willebrand disease
The Netherlands
Hall: Lomond
Moderator: Sabine Eichinger (Austria)
State of the Art
Coagulation factors crosstalk with endothelium
Spain
Hall: Alsh
Pierre Morange (France) and Banne Neneth (The Netherlands)
12.00 - 12.15
Short Break
12.15 - 13.15
Special Symposium (not part of main CME programme)
13.15 - 13.30
Short Break
13.30 - 14.30
Plenary Lecture
New development in Von Willebrand research
France
Hall: Lomond
Moderator: Flora Peyvandi (Italy)
14.30 - 15.15
Contact Activation
Oral Communications
Hall: Lomond
Moderators: Claire Whyte (United Kingdom) and Marco Heestermans (Germany)
- 14.30 – 14.45: Factor XII proline rich domain is essential for contact activation, Marco Heestermans, Germany
- 14.45 – 15.00: High molecular weight kininogen but not factor XII deficiency protects against acetaminophen-induced hepatotoxicity in mice, Rafal Pawlinski, United States
- 15.00 – 15.15: uPA-mediated plasminogen activation is enhanced by polyphosphate, Claire Whyte, United Kingdom
Von Willebrand Disease
Oral Communications
Hall: Alsh
Moderators: Eugenia Biguzzi (Italy) and Cédric Duval (United Kingdom)
- 14.30 – 14.45: Endothelial cells derived from induced pluripotent stem cells have the potential to model von Willebrand Disease, Matthew Sims, United Kingdom
- 14.45 – 15.00: Acquired Von Willebrand syndrome associated with monoclonal gammopathy, Eugenia Biguzzi, Italy
- 15.00 – 15.15: Determination of prevalence and features of main VWF synonymous variants of the CRMW database, Fanny Lassalle, France
Vessel Wall 1
Oral Communications
Hall: Boisdale
Moderators: Helen Mcpherson (United Kingdom) and Catherine Lemarie (France)
- 14.30 – 14.45: TLR3 promotes venous thrombosis through neutrophil recruitment, Maria Najem, France
- 14.45 – 15.00: CTL-2 is a VWF receptor involved in neutrophil activation, Gaia Zirka, France
- 15.00 – 15.15: DNAse-dependent but NETs-independent pathways of thrombus formation in vivo, Estelle Carminita, France
Platelets 2
Oral Communications
Hall: Carron
Moderators: Joanne Dunster (United Kingdom) and Irina Zotova (Russia)
- 14.30 – 14.45: Allelic polymorphism of platelet glycoprotein genes GPIa and GPIIb as a possible predictive marker of response to therapy in patients with primary immune thrombocytopenia, Irina Zotova, Russia
- 14.45 – 15.00: Platelet biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis, Alessandro Ciavarella, Italy
- 15.00 – 15.15: Effect of antiplatelet agents on bacterial induced platelet aggregation, Laurence Camoin-Jau, France
15.15 - 15.45
Coffee Break & Poster Viewing
15.45 - 17.00
Invited Integrated Symposium
Bleeding
Hall: Lomond
Moderators: Flora Peyvandi (Italy) and Tomas Lindahl (Sweden)
15.45 – 16.10: Immunogenicity of coagulation factors, Jan Voorberg, The Netherlands
16.10 – 16.35: Immunogenicity of monoclonal abs with a focus on Emicizumab, Gallia Levy, Italy
16.35 – 17.00: The role of rFVIIIFc in immune tolerance, Stefan Lethagen, Denark
Invited Integrated Symposium
Thrombosis
Hall: Alsh
Invited Integrated Symposium
Factor XIA
Hall: Boisdale
Moderators: Tilman Hackeng (The Netherlands) and Bérangère Joly (France)
Invited Integrated Symposium
OMICS
Hall: Carron
Moderators: Frits Rosendaal (The Netherlands) and Lucia Stanciakova (Slovakia)
15.45 – 16.10: Quantitative targeted mass spectrometry for measurement of coagulation factors and other plasma proteins, Yassene Mohammed, Canada/The Netherlands
16.10 – 16.35: Metabolomics, Michael Evans, United Kingdom
16.35 – 17.00: Application of metabolomics in studies of complex traits, Dennis Mook-Kanamori, The Netherlands
17.00 - 18.30
Poster Reception
17.30 - 18.30
Poster Sessions
19.00 - 00.00
Congress Dinner
Venue: Glasgow Science Centre (offsite)
The congress dinner of ECTH 2019 offers a great opportunity to meet and network with other experts in an informal setting, while tasting some local specialities from Scotland. The walking dinner will take place in a unique and iconic space: Glasgow Science Centre. This beautiful building is located on the Clyde waterfront, a vibrant place where historic Glasgow meets the modern city.
